EOFY SALE: iBOTTLE+ NOW $199 — WAS $399. FINAL HOURS · 30-day risk-free trial · Free shipping

Discussion – 

0

Discussion – 

0

Novel haemodialysis (HD) treatment employing molecular hydrogen (H 2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study


Hydrogen Water Studies

HaemodialysisLife Expectancy

Novel haemodialysis (HD) treatment employing molecular hydrogen (H 2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study

by Shigeru Kabayama, Ryo Yamamoto, Hirofumi Nakano, Hiromi Hamada, Hodaka Suzuki, Kazumasa Tsunoda, Mariko Miyazaki, Masaaki Nakayama, Naoyuki Osaka, Noritomo Itami, Ryoichi Nakazawa, Sadayoshi Ito, Yukio Maruyama

Abstract:

Recent studies have revealed unique biological characteristics of molecular hydrogen (H2) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering an H2 (30-80 ppb)-enriched dialysis solution by water electrolysis, and conducted a non-randomized, non-blinded, prospective observational study exploring its clinical impact. Prevalent chronic HD patients were allocated to either the E-HD (n = 161) group or the conventional HD (C-HD: n = 148) group, and received the respective HD treatments during the study. The primary endpoint was a composite of all-cause mortality and development of non-lethal cardio-cerebrovascular events (cardiac disease, apoplexy, and leg amputation due to peripheral artery disease). During the 3.28-year mean observation period, there were no differences in dialysis parameters between the two groups; however, post-dialysis hypertension was ameliorated with significant reductions in antihypertensive agents in the E-HD patients. There were 91 events (50 in the C-HD group and 41 in the E-HD group). Multivariate analysis of the Cox proportional hazards model revealed E-HD as an independent significant factor for the primary endpoint (hazard ratio 0.59; [95% confidence interval: 0.38-0.92]) after adjusting for confounding factors (age, cardiovascular disease history, serum albumin, and C-reactive protein). HD applying an H2-dissolved HD solution could improve the prognosis of chronic HD patients.

Read more:

https://doi.org/10.1038/s41598-017-18537-x

Related Articles:

Possible clinical effects of molecular hydrogen (H2) delivery during hemodialysis in chronic…

Background and aim: It is supposed that enhanced oxidative stress and inflammation are involved with the poor clinical outcomes in patients on chronic dialysis treatment. Recent studies have shown that molecular hydrogen (H2) is biologically active as an anti-inflammatory agent….

Year Published: 2017KidneyHaemodialysis

Improvement of the fraction of human mercaptalbumin on hemodialysis treatment using hydrogen-dissolved…

Background Oxidative stress (OS) is said to increase in hemodialysis therapy, so that the electrolyzed water-hemodialysis (EW-HD) dissolving hydrogen in hemodialysis fluid has been tried for the reduction of OS. It is reported that the risk of cardiovascular disease events…

Year Published: 2016KidneyHaemodialysis

Alkaline Water and Longevity: A Murine Study

The biological effect of alkaline water consumption is object of controversy. The present paper presents a 3-year survival study on a population of 150 mice, and the data were analyzed with accelerated failure time (AFT) model. Starting from the second…

Year Published: 2016Whole BodyAging

Dialysate With High Dissolved Hydrogen Facilitates Dissociation of Indoxyl Sulfate From Albumin

Protein-bound toxins such as indoxyl sulfate (IS) are not efficiently removed by conventional hemodialysis (HD). To improve the removal of IS, we performed an in vitro study to evaluate the effects of high dissolved hydrogen on the dissociation of IS…

Year Published: 2015KidneyHaemodialysis

Treatment with Hydrogen-Rich Saline Delays Disease Progression in a Mouse Model of…

Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motor neuron disease, and accumulating evidence indicates that oxidative mechanisms contribute to ALS pathology, but classical antioxidants have not performed well in clinical trials. The aim of this work was to…

Year Published: 2015BrainAmyotrophic Laterial Sclerosis

Sam Solomon

Research Scientist at iBottle

0 Comments

Submit a Comment

0
    0
    Your Cart
    Empty CartYour cart is emptyReturn to Shop
    Secure Checkout
    Free Shipping
    30-Day Money-Back